Abstracts tagged "Disease Activity"

Abstract Number: 867 • 2015 ACR/ARHP Annual Meeting
Simultaneous Measurement of 25-Hydroxyvitamin D and Procalcitonin in Granulomatosis with Polyangiitis (GPA): Differentiation of Activity from Infection?
Mariana O Perez¹, Ricardo M. Oliveira², Valéria Caparbo^3,4, Mauricio Levy-Neto⁵, Eloisa Bonfá⁴ and Rosa M R Pereira³, ¹Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²RDO Diagnósticos Médicos, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology DIvision, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Vitamin D acts as innate and adaptive immune response immunomodulator. 25-hydroxyvitamin D (25OHD) deficiency was reported to be associated with autoimmune diseases flares and…
Abstract Number: 1637 • 2015 ACR/ARHP Annual Meeting
TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis
Leslie Harrold^1,2, George W. Reed^1,2, Natalie Boytsov³, Carol L. Gaich³, Marc Mason⁴, Xiang Zhang³, Cynthia J. Larmore³, Sabrina Deveikis⁴ and Andre B. Araujo³, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: The purpose of this study was to describe the treatment patterns in biologic naïve initiators of TNF-inhibitors (TNFi) based on their disease activity over…
Abstract Number: 2321 • 2015 ACR/ARHP Annual Meeting
Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort
Hélène Che¹, Bernard Combe², Jacques Morel³, Alain G. Cantagrel⁴, Laure Gossec⁵ and Cédric Lukas⁶, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Rheumatology, Hopital Lapeyronie, Montpellier, France, ³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose: Activity of rheumatoid arthritis (RA) can be assessed by several outcome measures : joint counts, inflammatory syndrom but also auto-questionnaires such as global patient…
Abstract Number: 2605 • 2015 ACR/ARHP Annual Meeting
14-3-3η Positive Status and Higher Titres Are Associated with More Severe RA
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Serum 14-3-3η is an RA diagnostic marker that is associated with radiographic progression risk. In vitro studies describe 14-3-3η's potent, dose-dependent up-regulation of factors…
Abstract Number: 2740 • 2015 ACR/ARHP Annual Meeting
ACPA Positivity in the Elderly and Concomitant MTX Use in Younger May be Useful Predictive Factors for Superior Clinical Efficacy with Abatacept in Japanese Biological-Naïve RA Patients
Masahiro Sekiguchi¹, Takao Fujii², Masayasu Kitano¹, Kiyoshi Matsui¹, Kenji Miki³, Hideo Hashimoto⁴, Akira Yokota⁵, Aihiro Yamamoto⁶, Takashi Fujimoto⁷, Toshihiko Hidaka⁸, Naoki Shimmyo⁹, Keiji Maeda¹⁰, Takanori Kuroiwa¹¹, Ichiro Yoshii¹², Kosaku Murakami¹³, Koichiro Ohmura¹³, Satoshi Morita¹⁴, Yutaka Kawahito⁶, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁶ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Dept of Rheum/Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁴Rheumatology, Rinku Hashimoto Rheumatology Orthopaedics, Izumisano Osaka, Japan, ⁵Yokota Clinic for Rheumatology, Osaka, Japan, ⁶Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁷Nara Medical University, Kashihara, Japan, ⁸Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ⁹Department of Rheumatology, Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹⁰Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ¹¹Department of Internal Medicine, Yukioka Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Rheumatology & Clin Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁴Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Osaka Rheumatology Clinic, Osaka, Japan, ¹⁶Dept of Rheum & Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Sustained clinical remission is crucial in the RA. However, baseline predicting factors for sustained clinical remission in RA patients treated with abatacept (ABT) are…
Abstract Number: 3183 • 2015 ACR/ARHP Annual Meeting
The Clinical and Economic Costs of Not Achieving Remission in Rheumatoid Arthritis
Jeffrey R. Curtis¹, Lang Chen^1,2, Meredith Kilgore³, Huifeng Yun⁴ and Jeffrey D. Greenberg⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Bimingham, Birmingham, AL, ³Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Corrona, LLC, Southborough, MA
Background/Purpose: Treat to target guidelines recommend achieving a state of remission or low disease activity for rheumatoid arthritis (RA) patients. However, the benefit of lower…
Abstract Number: 309 • 2015 ACR/ARHP Annual Meeting
Plasma Levels of Heat Shock Protein 90 Are Increased in Idiopathic Inflammatory Myopathies and Correlate with Disease Activity, Skeletal Muscle, Heart and Lung Involvement
Hana Storkanova¹, Olga Krystufkova², Martin Klein³, Herman F Mann¹, Lucia Vernerova², Maja Spiritovic⁴, Josef Zámecník⁵, Karel Pavelka⁶, Ladislav Senolt³, Jiri Vencovsky¹ and Michal Tomcík¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁵Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, ⁶Charles University, Prague, Czech Republic
Background/Purpose: Heat shock proteins (Hsps) are chaperones playing important roles in skeletal muscle physiology, adaptation to exercise or stress, and in activation of inflammatory cells.…
Abstract Number: 596 • 2015 ACR/ARHP Annual Meeting
Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
Letty G.A. Versteeg¹, Laura M.M. Steunebrink¹, Ina H. Kuper¹, Peter M. ten Klooster², Arie E. van der Bijl³, Harald E. Vonkeman⁴ and Mart A.F.J. van de Laar¹, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Pcgr, University of Twente, Enschede, Netherlands, ³Isala Klinieken, Zwolle, Netherlands, ⁴Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Treat-to-target (T2T) in early Rheumatoid Arthritis (RA) has been successfully implemented in daily clinical practice. Patients achieve remission very early and during a follow-up…
Abstract Number: 926 • 2015 ACR/ARHP Annual Meeting
Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through a Data-Driven Approach
Anna-Birgitte Aga¹, Elisabeth Lie², Inge C Olsen², Hilde Berner Hammer³, Till Uhlig⁴, Désirée van der Heijde^5,6, Tore K. Kvien², Espen A. Haavardsholm² and the ARCTIC study group, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁶Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: No consensus exists regarding which joints and tendons should be systematically assessed by ultrasonography (US) to assess inflammation in rheumatoid arthritis (RA). Validity and…
Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting
Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Jose L. Pablos¹, Navarro Sarabia F², Francisco J. Blanco³, Jose Andres Roman Ivorra⁴, Alberto Alonso⁵, Emilio Martin-Mola⁶ and Miguel Cantalejo-Moreira⁷, ¹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ²Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ³Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology, H.U. P. La Fe, Valencia, Spain, ⁵H Cruces, Baracaldo, Spain, ⁶H La Paz, Madrid, Spain, ⁷Rheumatology Unit, Hospital de Fuenlabrada, Fuenlabrada, Spain
Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…
Abstract Number: 2468 • 2015 ACR/ARHP Annual Meeting
Antibodies to Histocompatibility Antigens in Juvenile Systemic Lupus Erythematosus Patients
Ana L Rodríguez-Lozano¹, Anne M. Stevens², Jessica M Foster³, Marisa S. Klein-Gitelman⁴, Hermine I. Brunner⁵, Elizabeth Field⁶, Ann M Reed⁷ and Karen Onel⁸, ¹Immunology, Instituto Nacional de Pediatria, Mexico City, Mexico, ²Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, ³Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ⁴Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Internal Medicine, University of Iowa, Iowa City, IA, ⁷Department of Pediatrics, Duke University, Durham, NC, ⁸Pediatric Rheumatology, Univ of Chicago, Chicago, IL
Background/Purpose: Microchimerism with HLA mismatched maternal cells can be readily demonstrated in normal individuals and is now established as a normal biological phenomenon. Pediatric SLE…
Abstract Number: 2608 • 2015 ACR/ARHP Annual Meeting
The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission
Ricardo J.O. Ferreira^1,2, Cátia Duarte^1,3, Sylvie Batista³, Catarina Medeiros³, J.P. Sousa³, Gisela Eugénio¹, Carlos Costa¹, Pedro Carvalho¹, Joana F. Ferreira¹, Margarida Coutinho^1,4, Maria J. Salvador^1,4, Laure Gossec⁵ and J.A.P. da Silva^3,6, ¹Rheumatology, Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal, ²Health Sciences Research Unit: Nursing (UICISA: E), Coimbra, Portugal, ³Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁴Clínica Universitária de Reumatologia, Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁵Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁶Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal
Background/Purpose: The "Rheumatoid Arthritis Impact of Disease" (RAID) score is a Patient Reported Outcome (PRO) that comprises seven domains of disease[1], that may reflect the…
Abstract Number: 2863 • 2015 ACR/ARHP Annual Meeting
Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa³, Emilio Martín-Mola¹, Daniel Seoane-Mato⁴ and Juan D. Cañete⁵, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: In patients with axial spondyloarthritis (axSpA), anti-TNF therapy is successful for clinically improving signs and symptoms of the disease. However, there is no clear…
Abstract Number: 3184 • 2015 ACR/ARHP Annual Meeting
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Sofia Ramiro¹, Robert B.M. Landewé², Désirée van der Heijde¹, Oliver FitzGerald³, Mikkel Østergaard^4,5, Joanne Homik⁶, Ori Elkayam⁷, J Carter Thorne⁸, Margaret Larche⁹, Gianfranco Ferraccioli¹⁰, Marina Backhaus¹¹, Gilles Boire¹², Bernard Combe¹³, Thierry Schaeverbeke¹⁴, Alain Saraux¹⁵, Maxime Dougados¹⁶, Silvano Adami¹⁷, Marcello Govoni¹⁸, Luigi Sinigaglia¹⁹, Alain G. Cantagrel²⁰, Cornelia F. Allaart¹, Cheryl Barnabe²¹, Clifton O. Bingham III²², Paul P. Tak²³, Dirkjan van Schaardenburg²⁴, Hilde Berner Hammer²⁵, Rana Dadashova²⁶, Edna Hutchings²⁶, Joel Paschke²⁶ and Walter Maksymowych²⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ⁶Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁰Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Rheumatology, Pellegrin University Hospital, Bordeaux, France, ¹⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁶Cochin Hospital, Paris Descartes University, Paris, France, ¹⁷University of Verona, Verona, Italy, ¹⁸University of Ferrara, Ferrara, Italy, ¹⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²⁰Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ²¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²²Rheumatology, Johns Hopkins University, Baltimore, MD, ²³Division of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²⁶CaRE Arthritis, Edmonton, AB, Canada, ²⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A Treat-to-Target approach (T2T), treating patients with RA towards a target, either remission or low disease activity (T2T-REM or T2T-LDA), is nowadays recommended. However…
Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Thaschawee Arkachaisri^1,2, Justin Hung Tiong Tan¹, Manasita Tanya¹, Sook Fun Hoh³, Lena Das⁴ and Jing Yao Leong^5,6, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁵Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ⁶SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].